Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB3219 - Provider product page
- Provider
- R&D Systems
- Product name
- Human/Mouse/Rat PRL-3 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects endogenous human, mouse and rat PRL-3 in Western blots. In Western blots, this antibody does not cross-react with recombinant human PRL-1 or PRL-2.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
O75365- Isotype
- IgG
- Antibody clone number
- 334402
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Tumor necrosis factor α-induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-κB signaling.
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Trenkmann M, Brock M, Gay RE, Michel BA, Gay S, Huber LC
Arthritis and rheumatism 2013 Apr;65(4):916-27
Arthritis and rheumatism 2013 Apr;65(4):916-27
Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M
International journal of cancer 2010 Aug 1;127(3):543-54
International journal of cancer 2010 Aug 1;127(3):543-54
Expression and prognostic impact of PRL-3 in lymph node metastasis of gastric cancer: its molecular mechanism was investigated using artificial microRNA interference.
Wang Z, He YL, Cai SR, Zhan WH, Li ZR, Zhu BH, Chen CQ, Ma JP, Chen ZX, Li W, Zhang LJ
International journal of cancer 2008 Sep 15;123(6):1439-47
International journal of cancer 2008 Sep 15;123(6):1439-47
A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie P, Perrotta A, Bian H, Reidhaar-Olson JF, Bliss SA, Olivier AR, Sergi JA, Fry D, Danho W, Ritland S, Fotouhi N, Heimbrook D, Niu H
Cancer research 2008 Feb 15;68(4):1162-9
Cancer research 2008 Feb 15;68(4):1162-9
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Human/Mouse/Rat PRL-3 by Western Blot. Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line, Neuro-2A mouse neuroblastoma cell line, and Nb2-11 rat lymphoma cell line. PVDF membrane was probed with 0.3 µg/mL of Human/Mouse/Rat PRL-3 Monoclonal Antibody (Catalog # MAB3219) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for PRL-3 at approximately 22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
